Rheumatology Medical News about Systemic JIA

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
CMS Re-Validates Enrollment of Big Billers

Dorothy J. Schirf, MD

Technology Advances

Circulating Breast Cancer Cells Validated as Index of Metastases

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Systemic JIA: new developments in the understanding of the pathophysiology and therapy
Best Practice & Research: Clinical Rheumatology, 10/28/09

Vastert SJ et al. – Systemic juvenile idiopathic arthritis (sJIA) is a rare, systemic inflammatory disease classified as a subtype of JIA. Treatment has been based on glucocorticosteroids in combination with disease–modifying drugs such as methotrexate. Recently, remarkable improvement has been observed with IL–1 and IL–6 targeted therapies. These therapies might also change the long–term outcome of this disease.

<< Previous
Angiotensin converting enzyme DD genotype is associated with...

Next >>
Developing outcome measures for paediatric rheumatic diseases